Duke Hematologic Malignancies & Cellular Therapy
@DukeHMCT
Followers
631
Following
2K
Media
231
Statuses
1K
Division within @dukemedicine and multidisciplinary program within @DukeCancer focused in blood cancer, stem cell transplantation, and cell & gene therapy.
Durham, NC
Joined May 2019
Finishing strong with Monday presentations by our @DukeCancer faculty at #ASH25! Featuring @AndreaSitlinger @ChenyuLinMD @tomleblancMD
0
1
1
A strong start to #ASH25 with @LindsayReinMD and #HarryErba kicking off the Friday Satellite Symposia!
0
0
2
DCI is participating in a national clinical trial that could reshape the future of CAR T-cell therapy for patients with aggressive lymphoma. https://t.co/GG6q0Jmx92
@DukeMedSchool | @DukeHealth | @DukeHMCT
0
4
5
A warm welcome to our newest faculty member, Dr. Alexander Dew! Dr. Dew joins @DukeCancer from Walter Reed, where he had served as director of autologous stem cell transplantation. He sees patients with plasma cell disorders, including #myeloma. https://t.co/NbPXMkCx5C
0
0
2
CAR #HEMATOTOX is associated with brexu-cel response, survival, and neutrophil recovery in #ALLsm. Great collaboration with @MSKCancerCenter Yannis Valtis & Jae Park, and #ROCCA consortium @StanfordCancer @LoriMuffly @UChicagoLeuk @RoloffGreg. @DukeCancer
https://t.co/SW3mEvE5AM
0
1
4
Take a look at this @FrontiersIn mini-review of reduced & weekly dosing of selinexor in #myeloma, with senior author @Cristin53875581
https://t.co/AbEUi4MDlU
0
0
3
Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm
https://t.co/eOFcea9ahg
1
3
10
Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses. #MDS | @tomleblancMD @DukeCancer
https://t.co/OHQYNeDOFx
targetedonc.com
During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.
0
1
3
Take a look at this review of advancements in countermeasures against #radiation injuries from the Centers for Medical Countermeasures against Radiation Consortium (CMCRC), with former @DukeHMCT division chief #NelsonChao as senior author. https://t.co/JKtG83Gd6A
pubmed.ncbi.nlm.nih.gov
The Centers for Medical Countermeasures against Radiation Consortium (CMCRC) has provided a strong research foundation for the radiobiology science that will follow. After 20 years, however, the...
0
0
0
This @CIBMTR retrospective study showed that solid organ transplant outcomes following stem cell transplantation varied depending on the organ transplanted. Liver transplants had worse outcomes compared to kidney transplants. Featuring @horwi001 as a co-author.
pubmed.ncbi.nlm.nih.gov
In this study, liver SOT recipients had inferior outcomes. However, renal and thoracic SOT recipients after HCT have acceptable outcomes compared with those of the general SOT population, and thus,...
0
0
0
The BELLINI trial showed that Vd-ven had worse overall survival than Vd-placebo in patients with relapsed multiple #myeloma, indicating that #venetoclax should be avoided in the general R/R myeloma population. Featuring @Cristin53875581 as an author. https://t.co/B0zvHomTOs
0
0
1
Congratulations to our faculty @tomleblancMD for this important work!
Multisite Randomized Trial of Inpatient #Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation. https://t.co/D8VIk3jg65
@ASCO @JCO_ASCO @JCOOP_ASCO
#PallOnc #PalliativeCare #SuppOnc
@Areejmd @tomleblancMD @MGHCancerCenter
0
0
3
Explore the complexities of chronic #GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies in this article from Targeted Oncology: https://t.co/ll0OeU2nP7 | @DukeHMCT @dukemedicine @DukeHealth
0
1
2
Preclinical and early phase clinical data suggests a role for dual #FLT3 and MDM2 inhibition using #quizartinib and #milademetan in FLT3-ITD mutated #AML, featuring faculty #HarryErba as a co-author. @CCR_AACR #leusm
https://t.co/IdPtV13cvC
0
0
1
This cross-sectional study in @JCOOP_ASCO showed that cancer survivors were more likely to get alcohol screening, with similar rates of alcohol intervention when needed, highlighting opportunities for improvement. Featuring Vice-Chief @AndreaSitlinger. https://t.co/pUMXgj67fG
ascopubs.org
PURPOSEMany cancer survivors consume alcohol above recommended limits, increasing their risk of recurrence, second cancers, and cancer-related mortality. Alcohol screening, brief intervention, and...
0
0
2
A multicenter study from the U.S. #MultipleMyeloma Immunotherapy Consortium demonstrated the safety and efficacy of #teclistamab in real-world patients, featuring @DukeU @ChenyuLinMD and #DanielSchrum @BloodCancerJnl #MMsm
https://t.co/hJANd60Edi
0
2
9
We are hiring for a Quality Program manager position for the @DukeCancer @DukeHealth Adult and Pediatric Transplant, Cellular Therapy, and Gene Therapy program. Apply here: https://t.co/J5obx3rUBY
0
0
3